Autoinjector Patents: Who Leads, Where the Gaps Are 2026
- Filing activity peaked in 2019 at 18 families and has not returned to that level since — the 2022 midpoint sits at zero, pointing to a market that consolidated around fewer, more defensible designs rather than one still in a land-grab phase.
- The five most-cited records all trace to drug-cassette and multi-chamber autoinjector architectures with citation counts running from 65 to 92 — these are the foundational claims that later filers had to design around.
- United States and EPO filings account for 43 and 35 of the tracked records respectively against 15 PCT filings, showing applicants are choosing direct national/regional routes over broad international coverage at the drafting stage.
How the autoinjector patent field is shaped
Autoinjector and on-body injector patents sit at the intersection of mechanical device engineering and drug delivery regulation. The search corpus behind this page combines device-class filings under A61M5, A61M37 and A61M39 with claim language tied to viscous-formulation injection time, needle insertion depth, human-factors testing and combination-product regulation — the language that separates a generic syringe patent from one built for self-administered biologics. Publication lags filing by roughly 18 months, so any apparent drop in the most recent year understates real filing activity rather than reflecting an actual pullback.
The 118 families in this dataset span device housings, dose-confirmation mechanisms, drug-cassette systems and the human-factors testing rigs used to validate them before combination-product submission. Reading the filing trend alongside the IPC composition shows a field where the core mechanical claims were staked out early and later activity has shifted toward adjacent classes — containers, educational aids and gearing — rather than the primary device class itself.
Filing trend and technology composition
Two views of the same 118-family dataset: how filing activity has moved year over year, and which IPC subclasses the claims actually sit in.
A peak in 2019, then a flat-to-declining run
Filings rose to 18 in 2019 from 6 in 2017, then eased back with the 2022 midpoint reading zero. That pattern is more consistent with a field settling around established mechanical architectures than one still expanding its claim footprint — treat the most recent two years as understated given publication lag rather than as evidence of a stalled field.
A61M dominates; supporting classes are thin
Every record in the corpus touches A61M (devices for body fluids), the primary device class. The next-largest classes — A61J containers (7), G09B educational/demonstration aids (6), A61K medicinal preparations (4) and F16H gearing/transmissions (4) — are all in single digits, meaning claim activity outside the core mechanical device is comparatively sparse and may be worth a closer look for anyone drafting around dose-confirmation training aids or drive-mechanism gearing.
Shares are the percentage of the 118 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Autoinjectors and On-Body Delivery Devices with Eureka
This page is one run against one query. Ask Eureka your own question about autoinjectors and on-body delivery devices and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records in the corpus
GB2490723A — A syringe for human factors studies
Filed by The Medical House Limited, this record describes a syringe built specifically for human-factors study use: a barrel with a closed forward end and open rear end, a plunger rod and stopper assembly with a fluid passageway that lets liquid flow rearward through the stopper as the plunger advances, and an absorbent material positioned to capture that flow. The design lets test administrators observe and measure plunger force and fluid movement during simulated injections without dispensing the drug itself.Published 2012-11-14 — predates much of the human-factors claim language now standard in combination-product filings.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2014144096A1 | Drug cassette, autoinjector, and autoinjector system | 92 |
| 2 | WO2014143815A2 | Drug cassette, autoinjector, and autoinjector system | 86 |
| 3 | US20160022914A1 | Drug cassette, autoinjector, and autoinjector system | 74 |
| 4 | US20130274707A1 | Three-Chambered Autoinjector | 69 |
| 5 | US20110034879A1 | Automatic Injection Mechanism with Frontal Buttress | 65 |
| 6 | US20160120751A1 | Drug cassette, autoinjector, and autoinjector system | 63 |
| 7 | US8900197B2 | Automatic injection mechanism with frontal buttress | 60 |
| 8 | EP2698180A1 | Autoinjector | 56 |
| 9 | WO2009155277A1 | Automatic injection mechanism with frontal buttress | 55 |
| 10 | US20150290392A1 | autoinjector | 48 |
Citation counts are drawn from the searched corpus only and skew toward older filings by construction — read them as a measure of influence on later filers, not as a ranking of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the filing data actually tells you
Three read-throughs from the trend, citation and jurisdiction data — useful for deciding where to file and who to watch.
Peak has passed, at least on paper
The trend line rose from 6 families in 2017 to a peak of 18 in 2019, then flattened. Combined with recent-year momentum readings of 0 across every assignee tracked, this looks like a field where the foundational mechanical claims are largely staked and filers are waiting on regulatory or clinical signals before committing new claim sets.
Influence sits with drug-cassette architectures
The five most-cited records in the corpus — cited between 65 and 92 times — are dominated by drug-cassette and multi-chamber autoinjector system claims. Anyone drafting a new mechanical drive or cassette-loading claim should expect prior art searches to surface these families first.
Direct filing beats broad PCT coverage
United States and European filings outnumber PCT filings by a wide margin (43 and 35 versus 15), with Canada, Hong Kong and Austria trailing further behind. That split suggests applicants in this space are prioritising the two largest device-approval markets directly rather than deferring jurisdiction choice through the PCT route.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to autoinjectors and on-body delivery devices, with the prior art for and against each one.
Who holds the ground — and how thin the ties between them are
Co-assignee activity is minimal in this corpus: only 4 co-assignee pairs appear across 118 families, and none of the tracked assignees show filing activity in the latest year. That points to a field of largely independent filers rather than a tightly networked consortium of device and pharma partners.
Drug-cassette and multi-chamber system holders
The most-cited families in the corpus describe drug-cassette autoinjector systems and three-chambered autoinjector mechanisms — these are the claims that downstream device designs most often have to route around, based on citation concentration alone.
Fill-finish and device-service partnerships stay narrow
West Pharmaceutical Services appears in co-assignee pairings with both a named inventor and a device-programme partner, suggesting collaborative filing exists but remains limited to a small number of joint records rather than a broad partnering pattern.
No assignee shows fresh-year activity
Every assignee reviewed for recent-year momentum — including large pharmaceutical and device names — shows zero filings in the latest year. Given the 18-month publication lag, this is likely an artefact of the data cut-off rather than a genuine stop in R&D, but it means the newest strategic moves are not yet visible in the public record.
| Assignee | Recent year | YoY |
|---|---|---|
| Amgen Inc. | 0 | — |
| Sanofi-Aventis Deutschland GmbH | 0 | — |
| QUIO TECHNOLOGIES LLC | 0 | — |
| West Pharmaceutical Services, Inc. | 0 | — |
| Medimop Medical Projects Ltd. | 0 | — |
| Meridian Medical Technologies | 0 | — |
| Novo Nordisk A/S | 0 | — |
| West Pharmaceutical Services Israel Ltd. | 0 | — |
Where to take this analysis
The filing and citation patterns above point to specific next questions — most of which need claim-level reading rather than another aggregate count.
Map the drug-cassette claim family in detail
The top five most-cited records share a drug-cassette architecture. Reading their independent claims side by side would show exactly how much room remains for a new cassette-loading or dose-confirmation mechanism.
Explore claim charts in EurekaCheck the under-claimed branches against your own device
G09B training aids and F16H drive gearing both show single-digit filing counts relative to the 118-family core. That gap could be genuine white space or simply unindexed activity worth a targeted search.
Run a focused search in EurekaFrequently asked questions
This dataset tracks 118 patent families published between 2015 and mid-2026, drawn from a search combining autoinjector and on-body/wearable injector terminology with device-class codes A61M5, A61M37 and A61M39. That figure counts families, which is the fairer unit than raw document counts because it neutralises duplicate filings across jurisdictions for the same invention. It is not a count of granted patents, and the true total is somewhat higher once the most recent 18 months of publication lag are accounted for.
The most-cited records in the corpus — covering drug-cassette autoinjector systems and three-chambered autoinjector designs — are the ones later filers most often had to cite or design around, with citation counts running from 65 to 92. Beyond those foundational filings, the dataset shows a field of largely independent filers: only 4 co-assignee pairs appear across all 118 families, so there is little evidence of a tightly networked group of leading assignees. A full assignee ranking, updated as new families publish, is more reliable than naming a fixed leader from citation counts alone.
Filing activity rose from 6 families in 2017 to a peak of 18 in 2019, then flattened, with the 2022 midpoint reading zero. This is consistent with a field where core mechanical architectures — drive mechanisms, cassette systems, dose-confirmation features — were staked out early, leaving less open claim space for entirely new device-level filings. It does not necessarily mean R&D activity has stopped: publication lags filing by roughly 18 months, so the most recent years in any trend understate real activity, and recent-year momentum figures should be read with that lag in mind.
GB2490723A, filed by The Medical House Limited, describes a syringe purpose-built for human-factors studies — a barrel, plunger rod and stopper assembly with a fluid passageway that redirects flow rearward through the stopper during a simulated injection, captured by an absorbent material rather than dispensed as a real dose. Its claims are narrow to that testing-rig configuration; they would not block a commercial autoinjector's drug-delivery mechanism, but they are relevant prior art for anyone building a human-factors test fixture with a similar rearward-flow stopper design. Reading the full claim set against your own test-rig geometry is the only reliable way to confirm freedom to operate.
Relative to the 118 core A61M records, supporting IPC classes are thin: A61J containers appear in 7 records, G09B educational and demonstration aids in 6, A61K medicinal preparations in 4, and F16H gearing and transmissions in 4. That imbalance suggests dose-confirmation training aids, drive-mechanism gearing, and needle-insertion-depth sensing are comparatively under-claimed relative to the core mechanical device class. A thin count is not proof of open white space on its own — it can also mean the activity is indexed elsewhere — so it is worth confirming with a targeted claim-level search before committing a filing strategy to it.
Research Autoinjectors and On-Body Delivery Devices in depth with Eureka
Go past this page: query the whole autoinjectors and on-body delivery devices corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.